DK1124556T3 - Anvendelse af optisk rent (R)-tofisopam til behandling og forebyggelse af angstsygdomme - Google Patents

Anvendelse af optisk rent (R)-tofisopam til behandling og forebyggelse af angstsygdomme

Info

Publication number
DK1124556T3
DK1124556T3 DK99970920T DK99970920T DK1124556T3 DK 1124556 T3 DK1124556 T3 DK 1124556T3 DK 99970920 T DK99970920 T DK 99970920T DK 99970920 T DK99970920 T DK 99970920T DK 1124556 T3 DK1124556 T3 DK 1124556T3
Authority
DK
Denmark
Prior art keywords
prevention
treatment
tophisopam
anxiety disorders
optically pure
Prior art date
Application number
DK99970920T
Other languages
Danish (da)
English (en)
Inventor
Donald W Landry
Donald F Klein
Original Assignee
Vela Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1124556T3 publication Critical patent/DK1124556T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
DK99970920T 1998-10-27 1999-10-27 Anvendelse af optisk rent (R)-tofisopam til behandling og forebyggelse af angstsygdomme DK1124556T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10580398P 1998-10-27 1998-10-27

Publications (1)

Publication Number Publication Date
DK1124556T3 true DK1124556T3 (da) 2004-10-11

Family

ID=22307874

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99970920T DK1124556T3 (da) 1998-10-27 1999-10-27 Anvendelse af optisk rent (R)-tofisopam til behandling og forebyggelse af angstsygdomme

Country Status (16)

Country Link
EP (1) EP1124556B1 (OSRAM)
JP (2) JP2003522112A (OSRAM)
AT (1) ATE269705T1 (OSRAM)
AU (1) AU1451900A (OSRAM)
BR (1) BR9914899A (OSRAM)
CA (1) CA2348281A1 (OSRAM)
DE (1) DE69918322T2 (OSRAM)
DK (1) DK1124556T3 (OSRAM)
ES (1) ES2224751T3 (OSRAM)
GB (1) GB2367748A (OSRAM)
HK (2) HK1046500A1 (OSRAM)
IL (2) IL142803A0 (OSRAM)
NZ (1) NZ511744A (OSRAM)
PT (1) PT1124556E (OSRAM)
WO (1) WO2000024400A1 (OSRAM)
ZA (1) ZA200103376B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649607B2 (en) * 2001-05-18 2003-11-18 Vela Pharmaceuticals, Inc. Compositions and methods for treating or preventing convulsions or seizures
CN1662231A (zh) * 2002-04-24 2005-08-31 柏树生物科学公司 包括应激相关障碍在内的功能性躯体障碍的预防与治疗
US6638928B1 (en) * 2002-12-03 2003-10-28 Vela Pharmaceuticals, Inc. Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
US20040152695A1 (en) * 2002-12-03 2004-08-05 Vela Pharmaceuticals, Inc. Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5H-2,3-benzodiazepine and uses thereof
JP2006510634A (ja) 2002-12-03 2006-03-30 ヴェラ ファーマスーティカルズ インコーポレイテッド 1−(3,4−ジメトキシフェニル)−4−メチル−5−エチル−7−メトキシ−8−ヒドロキシ−5h−2,3−ベンゾジアゼピンの製薬組成物及びその用途
US6864251B2 (en) * 2002-12-03 2005-03-08 Vela Pharmaceuticals, Inc. Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
US7022700B2 (en) 2002-12-03 2006-04-04 Vela Pharmaceuticals, Inc. Method of increasing neutrophil production using optically-pure (R)-2,3-benzodiazepines
CA2525273C (en) * 2003-05-16 2012-04-17 Vela Pharmaceuticals, Inc. Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
JP2007513171A (ja) * 2003-12-03 2007-05-24 ヴェラ ファーマスーティカルズ インコーポレイテッド 2,3−ベンゾジアゼピン低投与量による上皮の炎症性疾患の治療
FR2870539B1 (fr) * 2004-05-19 2006-08-04 Greenpharma Sa Sa Nouvelles methodes et medicaments
US7541355B2 (en) 2005-05-23 2009-06-02 Vela Acquisition Corporation Conversion process for 2,3-benzodiazepine enantiomers
CN102836162A (zh) * 2012-04-10 2012-12-26 珠海亿邦制药股份有限公司 一种以托非索泮为活性成分的口服固体制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK118660B (da) * 1966-12-09 1970-09-21 Egyt Gyogyszervegyeszeti Gyar Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en) * 1970-11-06 1972-02-23 Egyt Gyogyszervegyeszeti Gyar New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU178516B (en) * 1978-05-05 1982-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing enanthiomeres of 1-bracket-3,4-dimethoxy-phenyl-bracket closed-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine and pharmacologically acceptable soles of the /-/-enanthiomere
HU209530B (en) * 1988-08-31 1994-07-28 Magnezitipari Muevek Rt Process for manufacturing of cromit-like, fire resistant materials

Also Published As

Publication number Publication date
DE69918322D1 (de) 2004-07-29
GB0111739D0 (en) 2001-07-04
JP2007211028A (ja) 2007-08-23
GB2367748A (en) 2002-04-17
ATE269705T1 (de) 2004-07-15
ES2224751T3 (es) 2005-03-01
CA2348281A1 (en) 2000-05-04
HK1046500A1 (zh) 2003-01-17
GB2367748A8 (en) 2002-12-19
HK1040908A1 (en) 2002-06-28
EP1124556A1 (en) 2001-08-22
BR9914899A (pt) 2001-07-17
NZ511744A (en) 2004-04-30
IL142803A (en) 2006-10-05
AU1451900A (en) 2000-05-15
IL142803A0 (en) 2002-03-10
WO2000024400A1 (en) 2000-05-04
ZA200103376B (en) 2003-09-09
EP1124556B1 (en) 2004-06-23
PT1124556E (pt) 2004-10-29
HK1040908B (en) 2005-04-22
JP2003522112A (ja) 2003-07-22
DE69918322T2 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
DK0804196T3 (da) Anvendelse af serotoninantagonister (5HT 3) til behandling af fibromyalgia
DK0840601T3 (da) THIP til behandling af søvnforstyrrelser
DK1371647T3 (da) Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse
DE69425267D1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DK0836601T3 (da) Fremgangsmåde til optisk oprensning af enantiomert beriget benzimidasolderivater
DK1112106T3 (da) Serotonerge 5HT2-agonister til behandling af glaukom
DK1047428T3 (da) Anvendelse af morpholinol til behandlingen af seksualforstyrrelser
DK1459750T3 (da) (S,S)-rebexetin til behandling af fibromyalgi og andre somatoforme lidelser
DK1539166T3 (da) Farmaceutiske sammensætninger indeholdende dextromethorphan og quinidin til behandling af neurologiske sygdomme
DK0739212T3 (da) Anvendelse af interleukin-12 til forebyggelse af transplantat-vs.-værtssygdom
DK0896539T3 (da) Anvendelse af optisk rent (+)-norcisaprid til behandling af emesis og forstyrrelser i centralnervesystemet
DE69924375D1 (de) Verwendung von optisch reinem (+)-norcisapride für die behandlung des reizdarmsyndroms
DK0786991T3 (da) Polyaminforbindelsre til behandling af proliferative karsygdomme
DK1165510T3 (da) 1-arensulfonyl-2-aryl-pyrrolidin- og -piperidinderivater til behandling af CNS-lidelser
DE69918322D1 (de) Verwendung von optisch reinem (r)-tofizopam zur behandlung und pravention von angststörungen
DK0556332T3 (da) Substituerede tetrahydropyridiner og hydroxypiperidiner som midler til behandling af centralnervesystemet
DK0969845T3 (da) Nye terapeutiske kombinationer af mirtazapin og antipsykotika til behandling eller forebyggelse af psykotiske sygdomme
DK0655243T3 (da) Melatoninderivater til anvendelse ved behandling af søvnlidelser
NO990450D0 (no) Behandling av sinnslidelser
DK1121356T3 (da) 3-tetrahydropyridin-4-yl-indoler til behandling af psykotiske lidelser
DK0906255T3 (da) Fremgangsmåde til fremstilling af enantiomert ren azetidin-2-carboxylsyre
DK1468686T3 (da) S-methyl-dihydro-ziprasidon til behandling af psykiatriske lidelser
DK1011678T3 (da) Anvendelse af mecamylamin til behandling af nikotin-responsive neuropsykiatriske lidelser
DK0910660T3 (da) Fremgangsmåde til fremstilling af optisk aktive aminer
DK0804199T3 (da) Anvendelse af penciclovir til behandling af postherpetisk neuralgi